Agammaglobulinemia
MONDO:0015977A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.
Also known as: agammaglobulinemia, Gammaglobulin Deficiency, Immunoglobulin Deficiency, antibody Deficiency
85 clinical trials for this condition and its sub-types, 16 tagged with Agammaglobulinemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Agammaglobulinemia
-
Syndromic agammaglobulinemia 7 trials · 37 incl. sub-types
3 sub-types
- Common variable immunodeficiency 29 trials · 31 incl. sub-types Sub-types →
- Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome 0 trials
- Transient hypogammaglobulinemia 0 trials Sub-types →
-
Activated PI3K-delta syndrome 5 trials · 6 incl. sub-types
2 sub-types
- Immunodeficiency 14 6 trials
- Immunodeficiency 36 with lymphoproliferation 0 trials
-
Isolated agammaglobulinemia 0 trials · 4 incl. sub-types
2 sub-types
- Bruton-type agammaglobulinemia 4 trials
- Autosomal agammaglobulinemia 1 trial Sub-types →
-
Good syndrome 0 trials
-
Congenital agammaglobulinemia 0 trials
-
Immunodeficiency 61 0 trials
Most studied deeper sub-types
-
Could a stem cell drug tame rare immune disease?
Disease control CompletedThis early-phase study tests whether Mozobil, a drug already used to boost stem cells for transplants, can safely raise white blood cell counts in people with WHIMS. WHIMS is a rare genetic condition that traps infection-fighting cells in the bone marrow, leading to frequent infe…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
Rare disease drug shows promise in reducing infections
Disease control CompletedThis study tested two drugs, plerixafor and G-CSF, in 20 people with WHIM syndrome, a rare genetic condition that causes frequent infections and warts. Participants received each drug for a year and tracked their infections. The goal was to see which drug better reduced infection…
Phase 2/3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can antibody infusions shield CLL patients from deadly infections?
Disease control CompletedThis study tested whether regular infusions of Panzyga (a concentrated antibody solution from donated blood) could prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. The trial included 247 adults with CLL who were recei…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New antibody infusion shows promise for immune deficiency patients
Disease control CompletedThis study tested a new intravenous immunoglobulin (IVIg) treatment called Kedrion IVIg 10% in 47 people with primary immunodeficiency, a condition where the immune system cannot make enough antibodies. The goal was to see if regular infusions of this antibody therapy could preve…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Are hidden immune defects causing your recurring infections? new study investigates.
Knowledge-focused CompletedThis study looked for hidden immune system problems in adults who get frequent or severe bacterial infections, like pneumonia or meningitis. Researchers screened 120 adults aged 18-65 to see how many had an undiagnosed primary immunodeficiency. The goal was to find out if these c…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC